Sana Biotechnology (NASDAQ:SANA) Given New $9.00 Price Target at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its price target trimmed by HC Wainwright from $11.00 to $9.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

SANA has been the subject of several other reports. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Citizens Jmp boosted their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. Wedbush assumed coverage on shares of Sana Biotechnology in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Finally, JMP Securities set a $8.00 price objective on Sana Biotechnology in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Trading Up 1.0%

Shares of NASDAQ:SANA traded up $0.04 on Friday, reaching $4.09. The company had a trading volume of 5,461,342 shares, compared to its average volume of 6,789,225. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $7.30. The firm’s 50 day simple moving average is $4.06 and its 200-day simple moving average is $3.34. The firm has a market capitalization of $972.63 million, a PE ratio of -4.22 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. As a group, equities research analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors have recently bought and sold shares of SANA. Nisa Investment Advisors LLC boosted its holdings in shares of Sana Biotechnology by 673.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares during the last quarter. Hoey Investments Inc. acquired a new position in Sana Biotechnology during the second quarter valued at $33,000. TD Waterhouse Canada Inc. purchased a new stake in Sana Biotechnology in the third quarter valued at $37,000. Lyell Wealth Management LP purchased a new stake in Sana Biotechnology in the third quarter valued at $37,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Sana Biotechnology during the 3rd quarter worth about $39,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.